BRUSSELS, June 10, 2011 /PRNewswire/ — Results from new post
hoc analyses assessing the effects of Neupro® (rotigotine
transdermal system) in Restless Legs Syndrome (RLS) and utilizing
novel surrogate markers suggested improved daytime functioning and
daytime symptoms, reduced RLS-related pain and improved mood and
depressive symptoms in patients with moderate to severe RLS. The
data were presented at the 15th International Congress of
Parkinson’s disease and Movement disorders in Toronto, Canada.
Daytime functioning and daytime symptoms in RLS
patients
RLS has been mainly associated with symptoms occurring in the
late evening and at night. However, epidemiological studies and
this post hoc analysis suggested that patients may also experience
daytime symptoms and report impairment of daytime functioning.
Results of a post hoc analysis of a six month double blind study
of rotigotine transdermal in 458 patients suggested improvement in
daytime functioning and daytime symptoms in patients treated with
rotigotine transdermal (1, 2 and 3 mg/24h, pooled data) than
placebo.
“Daytime functioning symptoms, such as symptoms in the
afternoon, sleepiness and tiredness due to bad sleep are a problem
for many patients with moderate to severe RLS, and can adversely
affect their ability to carry out everyday activities. While
additional studies are needed, this post hoc analysis suggested
that patients treated with rotigotine transdermal for 6 months may
experience improvements in daytime functioning and daytime symptoms
compared to those treated with placebo. These effects may be
explained by the 24 hour coverage of symptoms, whenever they occur,
with the application of transdermal rotigotine,” said Dr. Ralf
Kohnen, University of Erlangen-Nuremberg, Germany.
Significant improvements with rotigotine transdermal versus
placebo (from baseline to end of maintenance) were seen in a series
of measures of RLS symptom severity on the I
‘/>”/>
